GlassScriptPhysician profile
Chanta Pou
NPI 1023350485
$2,206.68
in general payments reported to CMS, 2019-2025
13 companies · $656 in 2025
The $656 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.05 · 2022: $338 · 2023: $541 · 2024: $645 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.39 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,222.32 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $225.52 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $119.75 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $105.13 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $105.13 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $99.01 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.58 | 2023-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $83.01 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $48.47 | 2025 | |
| Lundbeck LLC | $35.48 | 2023-2024 | Rexulti |
| Sage Therapeutics, LLC | $31.20 | 2024 | |
| Neuronetics, INC. | $23.95 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.13 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanta Pou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.